Sparfloxacin vs Ofloxacin in the Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis

1995, Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma, Am J Respir Crit Care Med, 152, S77 Woolcock, 1989, Epidemiology of chronic airways disease, Chest, 96, 302S, 10.1378/chest.96.3_Supplement.302S Chodosh, 1991, Treatment of acute bacterial exacerbations of chronic bronchitis: state of the art, Am J Med, 91, 87, 10.1016/0002-9343(91)90317-Q Reynolds, 1990, Chronic bronchitis and acute infectious exacerbations, 529 Rodnick, 1988, The use of antibiotics in acute bronchitis and acute bacterial exacerbations of chronic bronchitis, West J Med, 149, 347 Ellner, 1988, Management of acute and chronic respiratory tract infections, Am J Med, 85, 2, 10.1016/0002-9343(88)90456-1 Baquero, 1996, In vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens, J Antimicrob Chemother, 37, 1, 10.1093/jac/37.suppl_A.1 Isada, 1993, Pro: antibiotics for chronic bronchitis with exacerbations, Semin Respir Infect, 8, 243 Ball, 1995, Chemotherapy for chronic bronchitis: controversies, Presse Med, 24, 189 Cunha, 1996, Newer antimicrobial agents for use in acute bacterial exacerbations in chronic bronchitis, Adv Ther, 13, 313 Canton, 1992, In vitro activity of sparfloxacin compared with those of five other quinolones, Antimicrob Agents Chemother, 36, 558, 10.1128/AAC.36.3.558 Doern, 1995, Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract, Am J Med, 99, 3, 10.1016/S0002-9343(99)80303-9 Honeybourne, 1994, The concentration of sparfloxacin in lung tissues after single and multiple doses, Int J Antimicrob Agents, 4, 151, 10.1016/0924-8579(94)90004-3 Wise, 1996, A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses, J Antimicrob Chemother, 37, 57, 10.1093/jac/37.suppl_A.57 Nakashima, 1991, Phase I study of pyridone carboxylic acid antibacterial agent, sparfloxacin, Rinsho-Yakuri, 7, 1639 Mizuki, 1996, Pharmacokinetic interactions related to the chemical structures of fluoroquinolones, J Antimicrob Chemother, 37, A41, 10.1093/jac/37.suppl_A.41 Johnson, 1994, The effect of sparfloxacin on the steady-state pharmacokinetics of digoxin in healthy male volunteers, Pharm Res, 11, S Jonkman J, Crijns H, Surtees M. Phase I, open study of the effect of sparfloxacin (400 mg for 1 day followed by 200 mg for a further 6 days) on warfarin pharmacodynamics in 10 healthy volunteers. (Protocol AT-113). July 2, 1993; unpublished data; Rhône-Poulenc Rorer Gries, 1995, Cimetidine does not alter sparfloxacin pharmacokinetics, Int J Clin Pharmacol Ther, 33, 585 Shimada, 1991, Pharmacokinetics and clinical studies on sparfloxacin, Chemotherapy, 39, 234 Jaillon, 1996, Overview of electrocardiographic and cardiovascular safety data for sparfloxacin, J Antimicrob Chemother, 37, 161, 10.1093/jac/37.suppl_A.161 Woods, 1995, The clinician and the microbiology laboratory, 169 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 3rd ed; approved standard. NCCLS Document M7-A3 (vol 13), No. 25, 1993 Performance standards for antimicrobial disk susceptibility tests. 5th ed; approved standard. NCCLS Document M2-A5 (vol 13), No. 24, 1993 Butler, 1996, The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System, J Infect Dis, 174, 986, 10.1093/infdis/174.5.986 Chodosh, 1991, Use of quinolones for the treatment of acute bacterial exacerbations of chronic bronchitis, Am J Med, 91, 93, 10.1016/0002-9343(91)90318-R Hara, 1991, A multicenter double-blind comparative study of sparfloxacin and ofloxacin in the treatment of chronic respiratory tract infections [abstract 878], 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Sept 29-Oct 2, 245 Soejima, 1993, Clinical response of sparfloxacin in respiratory tract infections, Drugs, 45, 405, 10.2165/00003495-199300453-00175 Ortqvist, 1996, Oral empiric treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin, Chest, 110, 1499, 10.1378/chest.110.6.1499 Saito, 1987, Ofloxacin in respiratory tract infections: a review of the results of clinical trials in Japan, Drugs, 34, 83, 10.2165/00003495-198700341-00018 Grassi, 1987, Clinical efficacy of ofloxacin in lower respiratory tract infections, Drugs, 34, 80, 10.2165/00003495-198700341-00017 Rademaker, 1990, A double-blind comparison of low dose ofloxacin and amoxycillin/clavulanic acid in acute exacerbations of chronic bronchitis, J Antimicrob Chemother, 26, 75, 10.1093/jac/26.suppl_D.75 Soejima, 1995, Antichlamydial activities of newly developed fluoroquinolones and their potential future role in the treatment of chlamydial respiratory infections, Drugs, 49, 257, 10.2165/00003495-199500492-00061 Carbon, 1993, Quinolones in the treatment of lower respiratory tract infections in adult patients, Drugs, 45, 91, 10.2165/00003495-199300453-00016 Isada, 1994, Chronic bronchitis: role of antibiotics, 621 Marrie, 1996, Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course, Am J Med, 101, 508, 10.1016/S0002-9343(96)00255-0 Lietman, 1995, Fluoroquinolone toxicities: an update, Drugs, 42, 159, 10.2165/00003495-199500492-00026 Shimada, 1993, Clinical pharmacokinetics of sparfloxacin, Clin Pharmacokinet, 25, 358, 10.2165/00003088-199325050-00002 Tulkins, 1991, Intracellular distribution and activity of antibiotics, Eur J Clin Microbiol Infect Dis, 10, 100, 10.1007/BF01964420 Couraud, 1987, Diffusion of ofloxacin into human lung tissue, Drugs, 34, 37, 10.2165/00003495-198700341-00009 1997 Perea, 1990, Ofloxacin concentrations in tissues involved in respiratory tract infections, J Antimicrob Chemother, 26, 55, 10.1093/jac/26.suppl_D.55